New drug combo aims to stop deadly brain lymphoma from returning
NCT ID NCT04627753
First seen Apr 29, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study is for people with primary central nervous system (CNS) lymphoma who have finished initial treatment but cannot have a stem cell transplant. The goal is to see if a maintenance therapy with two drugs, lenalidomide and rituximab, can keep the cancer from coming back and improve survival. About 30 participants will take these drugs for up to two years, and researchers will track how long they live without the disease progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 135710, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.